Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of QLG1091 versus Rybelsus in type 2 diabetes inadequately controlled after metformin
CTR20261001Phase 3Active
- Sponsor
- Qilu Pharmaceutical
- Start
- May 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of QLG1091 in type 2 diabetes mellitus (T2DM), sponsored by Qilu Pharmaceutical. Started May 2026; status: active.
02
Drugs
QLG1091
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20261001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261001.